Cynthia Pussinen was named Chief Executive Officer of Estrella Immunopharma, Inc., effective October 25, 2026. As of November 4, 2026, Estrella Immunopharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 29, 2026, naming 1 appointment (Form 8-K, October 29, 2026).
Sell to companies like Estrella Immunopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Estrella Immunopharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-29. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Estrella Immunopharma, Inc. files it.
Also on the record for Estrella Immunopharma, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Estrella Immunopharma, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Estrella Immunopharma, Inc. and the records around it.
Estrella Immunopharma, Inc. elsewhere on the record
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Estrella Immunopharma, Inc.
Get an email when Estrella Immunopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Estrella Immunopharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Estrella Immunopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Estrella Immunopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-29 | In | Chief Executive Officer | 2026-10-25 | 8-K, 2026-10-29 |
Who leads Estrella Immunopharma, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Cynthia Pussinen, appointed, effective 2026-10-25 (filed 2026-10-29).
New leaders reset buying decisions — get the Full Report on Estrella Immunopharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Estrella Immunopharma, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Estrella Immunopharma, Inc.Every change, in the filing's words
Appointed: Cynthia Pussinen, Chief Executive Officer, effective 2026-10-25
On October 25, 2026, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company") appointed Cynthia Pussinen, age 57, as Chief Executive Officer of the Company and as a Class I director and Chairperson of the Board, in each case effective October 25, 2026.
- Ms. Pussinen is not expected to be named to any committee of the Board.
- Effective October 25, 2026, Cheng Liu, Ph.D., ceased to serve as Chief Executive Officer and was appointed Chief Scientific Officer; Dr. Liu continues to serve as President and as a director of the Company.
- From March 2026 to October 2026, Ms. Pussinen served as Managing Director, Biotech Investments, of Sorbie Bornholm Ltd., an investment firm focused on micro- and small-capitalization public companies, and since 2023 she has provided strategic and operational consulting services to life sciences companies and investors.
- From August 2023 to August 2024, she was Chief Executive Officer and a director of Sernova Corp., a clinical-stage cell therapy company, and from January 2021 to November 2022 she was Chief Technical Officer of Spark Therapeutics, Inc., a gene therapy company and a member of the Roche Group, where she was responsible for technical development, manufacturing and operations.
Tools for this story
Each opens in a new tab, filled in for Estrella Immunopharma, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.